Why Early Phase Speed Depends On Oncology Expertise

In early phase oncology development, speed is shaped long before the first patient is enrolled. The programs that move efficiently aren’t defined by compressed timelines, but by early scientific decisions made with confidence. Choices around patient populations, dose escalation, cohort design, biomarkers, and site readiness determine whether a study accelerates smoothly or stalls under the weight of amendments and rework. Without deep oncology expertise, early assumptions can unravel, slowing progress just as momentum should build. At the same time, expertise alone isn’t sufficient if teams can’t sustain or scale as programs expand globally.

Explore why early phase speed is as much a scientific challenge as an operational one, and how experienced oncology teams plan for downstream realities from day one.